Press Releases

GI Dynamics, Inc. Appoints Distributor for the Middle East

LEXINGTON, Massachusetts and SYDNEY, Australia – 26 June 2013 – GI Dynamics, Inc. (ASX: GID) today announced that it has appointed Al-Nozha Medical Est., based in Jeddah, Saudi Arabia, as the distributor of EndoBarrier®, GI Dynamics’ proprietary treatment for type 2 diabetes and/or obesity, in...

read more

GI Dynamics, Inc. Reports on Progress of the ENDO Trial

LEXINGTON, Massachusetts & SYDNEY, Australia – 25 April 2013 – GI Dynamics, Inc. (ASX: GID) today announced an update on the status of the ENDO Trial, its U.S. multi-center, pivotal clinical trial of EndoBarrier® for the treatment of patients who have uncontrolled type 2 diabetes and are...

read more

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity, was selected by an independent panel of international life sciences experts...

read more

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity, was selected by an independent panel of international life sciences experts...

read more
Page 2 of 3123